Interventions to prevent or cease electronic cigarette use in children and adolescents.
Journal
The Cochrane database of systematic reviews
ISSN: 1469-493X
Titre abrégé: Cochrane Database Syst Rev
Pays: England
ID NLM: 100909747
Informations de publication
Date de publication:
15 11 2023
15 11 2023
Historique:
pmc-release:
15
11
2024
medline:
27
11
2023
pubmed:
15
11
2023
entrez:
15
11
2023
Statut:
epublish
Résumé
The prevalence of e-cigarette use has increased globally amongst children and adolescents in recent years. In response to the increasing prevalence and emerging evidence about the potential harms of e-cigarettes in children and adolescents, leading public health organisations have called for approaches to address increasing e-cigarette use. Whilst evaluations of approaches to reduce uptake and use regularly appear in the literature, the collective long-term benefit of these is currently unclear. The co-primary objectives of the review were to: (1) evaluate the effectiveness of interventions to prevent e-cigarette use in children and adolescents (aged 19 years and younger) with no prior use, relative to no intervention, waitlist control, usual practice, or an alternative intervention; and (2) evaluate the effectiveness of interventions to cease e-cigarette use in children and adolescents (aged 19 years and younger) reporting current use, relative to no intervention, waitlist control, usual practice, or an alternative intervention. Secondary objectives were to: (1) examine the effect of such interventions on child and adolescent use of other tobacco products (e.g. cigarettes, cigars types, and chewing tobacco); and (2) describe the unintended adverse effects of the intervention on individuals (e.g. physical or mental health of individuals), or on organisations (e.g. intervention displacement of key curricula or learning opportunities for school students) where such interventions are being implemented. We searched CENTRAL, Ovid MEDLINE, Ovid Embase, Ovid PsycINFO, EBSCO CINAHL, and Clarivate Web of Science Core Collection from inception to 1 May 2023. Additionally, we searched two trial registry platforms (WHO International Clinical Trials Registry Platform; US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov), Google Scholar, and the reference lists of relevant systematic reviews. We contacted corresponding authors of articles identified as ongoing studies. We included randomised controlled trials (RCTs), including cluster-RCTs, factorial RCTs, and stepped-wedge RCTs. To be eligible, the primary targets of the interventions must have been children and adolescents aged 19 years or younger. Interventions could have been conducted in any setting, including community, school, health services, or the home, and must have sought to influence children or adolescent (or both) e-cigarette use directly. Studies with a comparator of no intervention (i.e. control), waitlist control, usual practice, or an alternative intervention not targeting e-cigarette use were eligible. We included measures to assess the effectiveness of interventions to: prevent child and adolescent e-cigarette use (including measures of e-cigarette use amongst those who were never-users); and cease e-cigarette use (including measures of e-cigarette use amongst children and adolescents who were e-cigarette current-users). Measures of e-cigarette use included current-use (defined as use in the past 30 days) and ever-use (defined as any lifetime use). Two review authors independently screened the titles and abstracts of references, with any discrepancies resolved through consensus. Pairs of review authors independently assessed the full-text articles for inclusion in the review. We planned for two review authors to independently extract information from the included studies and assess risk of bias using the Cochrane RoB 2 tool. We planned to conduct multiple meta-analyses using a random-effects model to align with the co-primary objectives of the review. First, we planned to pool interventions to prevent child and adolescent e-cigarette use and conduct two analyses using the outcome measures of 'ever-use' and 'current-use'. Second, we planned to pool interventions to cease child and adolescent e-cigarette use and conduct one analysis using the outcome measure of 'current-use'. Where data were unsuitable for pooling in meta-analyses, we planned to conduct a narrative synthesis using vote-counting approaches and to follow the Cochrane Handbook for Systematic Reviews of Interventions and the Synthesis Without Meta-analysis (SWiM) guidelines. The search of electronic databases identified 7141 citations, with a further 287 records identified from the search of trial registries and Google Scholar. Of the 110 studies (116 records) evaluated in full text, we considered 88 to be ineligible for inclusion for the following reasons: inappropriate outcome (27 studies); intervention (12 studies); study design (31 studies); and participants (18 studies). The remaining 22 studies (28 records) were identified as ongoing studies that may be eligible for inclusion in a future review update. We identified no studies with published data that were eligible for inclusion in the review. We identified no RCTs that met the inclusion criteria for the review, and as such, there is no evidence available from RCTs to assess the potential impact of interventions targeting children and adolescent e-cigarette use, tobacco use, or any unintended adverse effects. Evidence from studies employing other trial designs (e.g. non-randomised) may exist; however, such studies were not eligible for inclusion in the review. Evidence from studies using non-randomised designs should be examined to guide actions to prevent or cease e-cigarette use. This is a living systematic review. We search for new evidence every month and update the review when we identify relevant new evidence. Please refer to the Cochrane Database of Systematic Reviews for the current status of this review.
Sections du résumé
BACKGROUND
The prevalence of e-cigarette use has increased globally amongst children and adolescents in recent years. In response to the increasing prevalence and emerging evidence about the potential harms of e-cigarettes in children and adolescents, leading public health organisations have called for approaches to address increasing e-cigarette use. Whilst evaluations of approaches to reduce uptake and use regularly appear in the literature, the collective long-term benefit of these is currently unclear.
OBJECTIVES
The co-primary objectives of the review were to: (1) evaluate the effectiveness of interventions to prevent e-cigarette use in children and adolescents (aged 19 years and younger) with no prior use, relative to no intervention, waitlist control, usual practice, or an alternative intervention; and (2) evaluate the effectiveness of interventions to cease e-cigarette use in children and adolescents (aged 19 years and younger) reporting current use, relative to no intervention, waitlist control, usual practice, or an alternative intervention. Secondary objectives were to: (1) examine the effect of such interventions on child and adolescent use of other tobacco products (e.g. cigarettes, cigars types, and chewing tobacco); and (2) describe the unintended adverse effects of the intervention on individuals (e.g. physical or mental health of individuals), or on organisations (e.g. intervention displacement of key curricula or learning opportunities for school students) where such interventions are being implemented.
SEARCH METHODS
We searched CENTRAL, Ovid MEDLINE, Ovid Embase, Ovid PsycINFO, EBSCO CINAHL, and Clarivate Web of Science Core Collection from inception to 1 May 2023. Additionally, we searched two trial registry platforms (WHO International Clinical Trials Registry Platform; US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov), Google Scholar, and the reference lists of relevant systematic reviews. We contacted corresponding authors of articles identified as ongoing studies.
SELECTION CRITERIA
We included randomised controlled trials (RCTs), including cluster-RCTs, factorial RCTs, and stepped-wedge RCTs. To be eligible, the primary targets of the interventions must have been children and adolescents aged 19 years or younger. Interventions could have been conducted in any setting, including community, school, health services, or the home, and must have sought to influence children or adolescent (or both) e-cigarette use directly. Studies with a comparator of no intervention (i.e. control), waitlist control, usual practice, or an alternative intervention not targeting e-cigarette use were eligible. We included measures to assess the effectiveness of interventions to: prevent child and adolescent e-cigarette use (including measures of e-cigarette use amongst those who were never-users); and cease e-cigarette use (including measures of e-cigarette use amongst children and adolescents who were e-cigarette current-users). Measures of e-cigarette use included current-use (defined as use in the past 30 days) and ever-use (defined as any lifetime use).
DATA COLLECTION AND ANALYSIS
Two review authors independently screened the titles and abstracts of references, with any discrepancies resolved through consensus. Pairs of review authors independently assessed the full-text articles for inclusion in the review. We planned for two review authors to independently extract information from the included studies and assess risk of bias using the Cochrane RoB 2 tool. We planned to conduct multiple meta-analyses using a random-effects model to align with the co-primary objectives of the review. First, we planned to pool interventions to prevent child and adolescent e-cigarette use and conduct two analyses using the outcome measures of 'ever-use' and 'current-use'. Second, we planned to pool interventions to cease child and adolescent e-cigarette use and conduct one analysis using the outcome measure of 'current-use'. Where data were unsuitable for pooling in meta-analyses, we planned to conduct a narrative synthesis using vote-counting approaches and to follow the Cochrane Handbook for Systematic Reviews of Interventions and the Synthesis Without Meta-analysis (SWiM) guidelines.
MAIN RESULTS
The search of electronic databases identified 7141 citations, with a further 287 records identified from the search of trial registries and Google Scholar. Of the 110 studies (116 records) evaluated in full text, we considered 88 to be ineligible for inclusion for the following reasons: inappropriate outcome (27 studies); intervention (12 studies); study design (31 studies); and participants (18 studies). The remaining 22 studies (28 records) were identified as ongoing studies that may be eligible for inclusion in a future review update. We identified no studies with published data that were eligible for inclusion in the review.
AUTHORS' CONCLUSIONS
We identified no RCTs that met the inclusion criteria for the review, and as such, there is no evidence available from RCTs to assess the potential impact of interventions targeting children and adolescent e-cigarette use, tobacco use, or any unintended adverse effects. Evidence from studies employing other trial designs (e.g. non-randomised) may exist; however, such studies were not eligible for inclusion in the review. Evidence from studies using non-randomised designs should be examined to guide actions to prevent or cease e-cigarette use. This is a living systematic review. We search for new evidence every month and update the review when we identify relevant new evidence. Please refer to the Cochrane Database of Systematic Reviews for the current status of this review.
Identifiants
pubmed: 37965949
doi: 10.1002/14651858.CD015511.pub2
pmc: PMC10646968
doi:
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
CD015511Informations de copyright
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Références
BMC Public Health. 2022 Dec 10;22(1):2311
pubmed: 36496358
Am J Prev Med. 2015 Nov;49(5):686-693
pubmed: 26163170
Addict Behav. 2021 Feb;113:106698
pubmed: 33130463
Br J Gen Pract. 2006 Oct;56(531):768-74
pubmed: 17007707
Addict Behav. 2020 Feb;101:106177
pubmed: 31753541
Health Educ Behav. 2023 Oct;50(5):683-692
pubmed: 36722218
Addict Behav. 2021 Jan;112:106599
pubmed: 32950927
Tob Control. 2020 Mar 10;:
pubmed: 32156694
J Drug Educ. 2022 Mar;51(1-2):10-31
pubmed: 35788160
Drug Alcohol Depend. 2019 Aug 1;201:85-93
pubmed: 31200279
Am J Prev Med. 2019 Nov;57(5):592-600
pubmed: 31564599
Nicotine Tob Res. 2023 Feb 9;25(3):430-437
pubmed: 36006858
PLoS One. 2021 Sep 8;16(9):e0256044
pubmed: 34495974
Evid Based Med. 2017 Jun;22(3):85-87
pubmed: 28320705
J Med Libr Assoc. 2021 Jan 01;109(1):97-106
pubmed: 33424470
Children (Basel). 2022 Jun 22;9(7):
pubmed: 35883921
Health Commun. 2019 Mar;34(3):290-297
pubmed: 29236550
Pediatrics. 2021 May;147(5):
pubmed: 33875537
Am J Prev Med. 2022 Jun;62(6):953-960
pubmed: 35337694
Asian Am J Psychol. 2019 Sep;10(3):239-248
pubmed: 32395199
BMC Public Health. 2021 Jan 21;21(1):184
pubmed: 33478456
BMC Psychol. 2019 Dec 17;7(1):82
pubmed: 31847888
Nicotine Tob Res. 2003 Aug;5(4):473-83
pubmed: 12959785
BMJ Open. 2020 May 15;10(5):e031589
pubmed: 32414817
JAMA Intern Med. 2021 Jul 1;181(7):923-930
pubmed: 33999133
Am J Addict. 2019 Sep;28(5):361-366
pubmed: 31066987
Curr Addict Rep. 2020;7(4):520-532
pubmed: 33204602
JMIR Mhealth Uhealth. 2017 Aug 04;5(8):e116
pubmed: 28778850
Pharmacol Ther. 2021 Sep;225:107837
pubmed: 33753133
Int J Environ Res Public Health. 2022 Aug 14;19(16):
pubmed: 36011661
J Clin Epidemiol. 2014 Jan;67(1):56-64
pubmed: 24189091
Addict Behav. 2021 Jan;112:106519
pubmed: 32890911
Nicotine Tob Res. 2018 Jul 9;20(8):954-961
pubmed: 29106669
Int J Environ Res Public Health. 2017 Jan 04;14(1):
pubmed: 28054993
BMJ Open. 2016 Nov 7;6(11):e014288
pubmed: 27821601
Addict Behav. 2020 Oct;109:106473
pubmed: 32521287
BMC Public Health. 2020 Dec 14;20(1):1910
pubmed: 33317488
Addict Behav. 2019 Jun;93:86-92
pubmed: 30703667
Nicotine Tob Res. 2015 Jul;17(7):847-54
pubmed: 25481917
Int J Environ Res Public Health. 2022 Nov 25;19(23):
pubmed: 36497804
J Adolesc Health. 2021 Sep;69(3):519-522
pubmed: 33610402
J Clin Pharmacol. 2021 Aug;61 Suppl 2:S18-S36
pubmed: 34396553
Addict Behav. 2021 Mar;114:106726
pubmed: 33278717
Lancet Public Health. 2021 Sep;6(9):e661-e673
pubmed: 34274048
Health Promot Pract. 2021 Jan;22(1):18-20
pubmed: 32281882
Drug Alcohol Depend. 2023 May 1;246:109834
pubmed: 36963159
Cochrane Database Syst Rev. 2020 Oct 14;10:CD010216
pubmed: 33052602
Drug Alcohol Depend. 2022 Mar 1;232:109311
pubmed: 35123362
BMJ Open. 2015 Mar 10;5(3):e006976
pubmed: 25757946
Health Commun. 2019 Mar;34(3):352-360
pubmed: 29236554
Nicotine Tob Res. 2013 Oct;15(10):1655-62
pubmed: 23460656
Tob Control. 2016 May;25(3):355-9
pubmed: 26071428
Tob Use Insights. 2021 Nov 23;14:1179173X211050396
pubmed: 34866950
JMIR Res Protoc. 2023 Jan 27;12:e42956
pubmed: 36705967
Addict Behav. 2021 Apr;115:106795
pubmed: 33387976
Contemp Clin Trials. 2022 Aug;119:106840
pubmed: 35760339
Cochrane Database Syst Rev. 2023 Nov 15;11:CD015511
pubmed: 37965949
Aust N Z J Public Health. 2023 Jun;47(3):100060
pubmed: 37187076
Drug Alcohol Depend. 2016 Jun 01;163 Suppl 1:S54-9
pubmed: 27306732
BMC Public Health. 2023 Apr 12;23(1):683
pubmed: 37046211
Public Health Rep. 2020 Mar/Apr;135(2):220-229
pubmed: 31968177
Nicotine Tob Res. 2015 Mar;17(3):330-6
pubmed: 25125321
BMC Public Health. 2018 Jul 31;18(1):942
pubmed: 30064473
JAMA Netw Open. 2023 Mar 1;6(3):e231799
pubmed: 36917111
Nicotine Tob Res. 2020 Apr 21;22(5):859-860
pubmed: 31197320
Int J Environ Res Public Health. 2017 Dec 07;14(12):
pubmed: 29215555
Health Commun. 2016;31(1):129-38
pubmed: 25758192
JAMA Netw Open. 2022 Oct 3;5(10):e2236370
pubmed: 36227597
Subst Abuse Rehabil. 2010 Dec 06;1:23-33
pubmed: 24474850
J Adolesc Health. 2021 Apr;68(4):794-800
pubmed: 33039271
Addict Behav. 2021 Aug;119:106898
pubmed: 33894483
JAMA Pediatr. 2021 Jan 1;175(1):97-99
pubmed: 32804194
Malays J Med Sci. 2022 Oct;29(5):133-145
pubmed: 36474542
Front Public Health. 2020 Aug 04;8:377
pubmed: 32850598
Addict Behav. 2021 Feb;113:106664
pubmed: 33038677
J Pediatr Psychol. 2021 Jan 20;46(1):112-122
pubmed: 33120416
Aust N Z J Public Health. 2018 Jun;42(3):303-308
pubmed: 29528527
Drug Alcohol Rev. 2007 Nov;26(6):605-13
pubmed: 17943521
Prev Sci. 2020 Aug;21(6):807-819
pubmed: 32323166
JMIR Res Protoc. 2019 Feb 15;8(2):e12164
pubmed: 30767903
Nicotine Tob Res. 2020 Jun 12;22(7):1086-1097
pubmed: 31570931
Addict Behav. 2023 Jun;141:107637
pubmed: 36753933
Trials. 2021 Jan 6;22(1):31
pubmed: 33407805
Subst Abus. 2021;42(1):47-53
pubmed: 31825759
Tob Control. 2020 Jul;29(4):425-431
pubmed: 31253718
Contemp Clin Trials. 2023 Feb;125:107049
pubmed: 36521631